On 3/4/19 Silk Road Medical Filed for an upcoming $86 Million IPO. The Sunnyvale, CA based company has introduced the TCAR procedure intended to reduce the risk embolic debris entering the brain during interventional procedures related to the carotid artery. The filing did not specify a date. The company will trade on NASDAQ under the symbol, “SILK”.
To enable the TCAR procedure, Silk Road provides its ENROUTE Transcarotid Neuroprotection System. The system temporarily reverses the flow of blood in the carotid artery during surgical procedures. The blood is filtered to remove both large and small emboli and returned via the femoral vein. This is intended to remove the risk of small emboli that can reach the brain and cause minor brain infarcts.
The company's prospectus states that As of December 31, 2018, more than 7,750 TCAR procedures have been performed globally, including more than 4,600 in 2018.